$6.37 Billion is the total value of Avoro Capital Advisors LLC's 52 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 47.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $209,610,000 | -11.5% | 8,500,000 | -6.6% | 3.29% | -20.1% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $203,959,000 | -26.6% | 3,425,000 | -16.0% | 3.20% | -33.7% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $160,489,000 | -5.3% | 850,000 | -15.0% | 2.52% | -14.5% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $120,443,000 | -24.4% | 664,000 | -15.9% | 1.89% | -31.7% |
| KURA | Sell | KURA ONCOLOGY INC | $74,920,000 | -13.2% | 4,000,000 | -3.4% | 1.18% | -21.6% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $36,542,000 | -38.6% | 2,200,000 | -9.9% | 0.57% | -44.6% |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $29,525,000 | -42.7% | 1,545,000 | -48.5% | 0.46% | -48.2% |
| AVDL | Sell | AVADEL PHARMACEUTICALS PLCsponsored adr | $22,295,000 | -24.1% | 2,275,000 | -47.9% | 0.35% | -31.5% |
| MRUS | Sell | MERUS N V | $9,900,000 | -28.8% | 450,000 | -31.8% | 0.16% | -35.5% |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INCcall | $0 | – | -150,000 | -100.0% | -0.02% | – |
| ARPO | Exit | AERPIO PHARMACEUTICALS INC | $0 | – | -4,500,000 | -100.0% | -0.13% | – |
| ADAP | Exit | ADAPTIMMUNE THERAPEUTICS PLCsponsored adr | $0 | – | -2,024,400 | -100.0% | -0.15% | – |
| BCTG | Exit | BCTG ACQUISITION CORP | $0 | – | -800,000 | -100.0% | -0.16% | – |
| CNTA | Exit | CENTESSA PHARMACEUTICALS PLCsponsored ads | $0 | – | -500,000 | -100.0% | -0.19% | – |
| OLMA | Exit | OLEMA PHARMACEUTICALS INC | $0 | – | -876,986 | -100.0% | -0.43% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -935,000 | -100.0% | -0.52% | – |
| CNST | Exit | CONSTELLATION PHARMACEUTICALS INC | $0 | – | -3,210,000 | -100.0% | -1.89% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.